Hormonal gender reassignment therapy in Spain: Our experience in 236 patients;Tratamiento hormonal de reasignación de sexo en España: Nuestra experiencia en 236 casos

Revista Internacional de Andrologia

Volumn 5, Issue 3, 2007, Pages 212-217

  Becerra Fernández, Antonio ^a   Pérez, María Jesús Lucio ^b   Agelan, José Luis Llopis ^b  

^a NONE   (Spain)

^b NONE

Author keywords

Adverse effects; Hormone therapy; Hyperprolactinemia; Transsexual

Indexed keywords

EID: 35348820011     PISSN: 1698031X     EISSN: 16980409     Source Type: Journal    
DOI: 10.1016/S1698-031X(07)74059-1     Document Type: Article

References (26)

1. Eklund PLE, Gooren LJG, Bezemer PD. Prevalence of transsexualism in the Netherlands. Br J Psychiatry. 1988;152: 641-8.
2. Hamburger C. Endocrine treatment of male and female transsexualism. En: Green R, Money J, editors. Transsexualism and Sex Reassignment. Baltimore: John Hopkins University; 1969. p. 291-307.
3. Van Kesteren PJM, Asscheman H, Megens JAJ, Gooren LJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997;47:337-42.
4. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med. 1981;305:612-8.
5. Royal College of General Practitioners Oral Contraception Study. Mortality among oral-contraceptive users. Lancet. 1977;2:727-31.
6. Vischer U. Estrogens and atherosclerosis: a direct protective effect on the vascular wall? Eur J Endocrinol. 1997;137:343-4.
7. Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet. 1967;124:1011-7.
8. Wilson JD, Griffin JE. The use and mis-use of androgens. Metabolism. 1980;29:1278-95.
9. Walker PA, Berger JC, Green R, Laub DR, Reynolds CL, Wollman L. Standards of care. The hormonal and surgical sex reassignment of gender dysphoric persons. Arch Sex Behav. 1985;14:79-90.
10. Friedewald WT, Levy IR, Fredrickson DS. Estimation of plasma low density lipoprotein cholesterol concentration without the use of a preparative ultracentrifugation. Clin Chem. 1972;18:499-509.
11. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence to atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol. 1992;70:733-7.
12. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol. 1997;37:477-515.
13. Moffatt R, Wallace M, Sady S. Effects of anabolic steroids on lipoprotein profiles of female weight lifters. Physician Sports Med. 1990;18:106-10.
14. Märin P, Krotkiewski M, Björntorp P. Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues. Eur J Int Med. 1992;1:329-36.
15. Gooren LJG. Testosteron: a good-hearted hormone? En: Abstract book of Satellite Symposium on testosterone replacement therapy. Sevilla: IV European Congress of Endocrinology; 1998. p. 13.
16. Asscheman H, Gooren LJG, Eklund PLE. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989;38:869-73.
17. Gooren LJG. The endocrinology of transexualism: a review and commentary. Psychoneuroendocrinology. 1990;15:3-14.
18. Pérez RL, Machiavelli GA, Romano MI, Burdman JA. Prolactin release, oestrogens and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats. J Endocrinol. 1986;108:399-403.
19. Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc. 1990;65:461-74.
20. Ben Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocrine Rev. 1985;6:564-89.
21. Luciano AA, Sherman BM, Chapler FK, Hauser KS, Wallace RB. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol. 1985;65:506-10.
22. Gooren LJG, Harmsen-Louman W, Van Kessel H. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Clin Endocrinol (Oxf). 1985;22:201-7.
23. Asscheman H, Gooren LJG, Assies J, Smits JPH, de Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf). 1988;28:583-8.
24. Gooren LJG, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metabol. 1988;66:444-6.
25. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A study morphologic study. Arch Pathol Lab Med. 1994;118:562-5.
26. Gooren L, van der Veen EA, van Kessel H. Modulation of prolactin secretion by gonadal steroids in men. En: Macleod RM, Scampagnini M, editors. Central and Peripheral Regulation of Prolactin Function. New Cork: Raven Press; 1980. p. 373.